Chapter 12 - Solid Lipid Nanoparticles in Drug Delivery: Opportunities and Challenges

https://doi.org/10.1016/B978-0-323-42978-8.00012-7Get rights and content

Abstract

Since their introduction in the early 1990s, solid lipid nanoparticles (SLNs) have received tremendous attention in drug delivery because of their ability to carry and solubilize lipophilic drugs and their small particle size, resulting in increased cellular uptake and absorption. SLNs are composed of physiological lipids, which reduce the risk of acute and chronic toxicity. However, SLNs are prone to instabilities because of their complex crystallization behavior due to the occurrence of polymorphic transitions. This chapter summarizes various aspects of SLNs such as components and production of SLNs, drug loading, drug release, stability, and application of SLNs in drug delivery. This chapter also provides a summary of SLNs as a potential carrier of anticancer drugs, one of the most aggressively expanding areas of research. A special emphasis is placed on the stability and toxicity issues associated with SLNs and their diagnostic applications.

References (0)

Cited by (23)

  • Nanocarrier mediated drug delivery as an impeccable therapeutic approach against Alzheimer's disease

    2022, Journal of Controlled Release
    Citation Excerpt :

    They are the lipid based nanocarriers that are synthesized from solid lipids or mixtures in an aqueous dispersion at a concentration ranging from 0.1 %w/w to 30%w/w and the formulation is stabilized by adding emulsifier at a concentration of 0.5%w/w to 5%w/w and SLNs are solid at body temperature [170,185–190]. Because of their potential to transport and solubilize lipophilic drug molecules, lipid-based systems such as SLNs have piqued interest in drug formulation and development [191]. The formulation of SLNs includes homogenization, microemulsion, solvent diffusion-evaporation techniques [192].

  • Understanding molecular mechanisms of biologics drug delivery and stability from NMR spectroscopy

    2021, Advanced Drug Delivery Reviews
    Citation Excerpt :

    These SLN nanoparticles ensure higher drug stability and prolonged release because of their crystalline structure. On the other hand, the high crystallinity of solid lipid nanoparticles can cause limited drug loading and drug expulsion due to polymorphic transitions of solid lipid [139]. Hence many improved systems such as oil-loaded SLNs (nanostructured lipid carriers, NLC), and calixarene-based SLNs were developed and characterized to resolve these issues.

  • Intranasal delivery of nanostructured lipid carriers, solid lipid nanoparticles and nanoemulsions: A current overview of in vivo studies

    2021, Acta Pharmaceutica Sinica B
    Citation Excerpt :

    From the 37 approved nasal medicines, 1 is a TrueTear™ device for neuropathic corneal pain, 2 contain influenza vaccines and 34 contain different drugs, being midazolam, ketamine and dexmedetomidine the most prevalent. However, to our knowledge, there are no nasal formulations of SLNs, NLCs and NEs marketed, although the use of these nanocarriers has been studied to improve the drug deliver through other routes of administration, such as oral, parenteral, cutaneous, ocular, rectal and pulmonary, and for cosmetics45,48,96. Despite the several investigations that have been carried out, only cosmetic products with SLNs and NLCs have been approved37,41,42,97,98.

View all citing articles on Scopus
View full text